Full Press Release Details
Lexaria Intellectual Property Update
Kelowna, BC / May 15, 2015 / Lexaria, Corp. (OTCQB:LXRP)
(CSE:LXX) (the Company ) provides the following update and information
regarding its patent-pending technology; how it relates to the delivery of
certain active ingredients such as CBD and THC, and how it relates also to
Lexaria has caused to be filed on April 28, 2015 and May 14,
2015, the latest in a line of provisional patent applications with the United
States Patent and Trademark Office regarding its technology that were originally
filed beginning in June, 2014. Lexaria s new patent-pending technology is
directed to food and beverage compositions infused with cannabinoids e.g., THC
and/or CBD that provide enhanced cannabinoid oral bioavailability. We expect
the United States Patent and Trademark Office to publish our provisional patent
applications roughly in December 2015.
Lexaria s proprietary process infuses lipids within foods and
beverages with cannabinoids and produces compositions with synergistically
enhanced cannabinoid absorption and bioavailability. The cannabinoid infused
food and beverage compositions have the added benefit of masking the inherent
unpleasant taste of cannabinoids to allow for better patient compliance with
therapeutically administered cannabinoids.
It is important to understand certain facts:
Smoked or inhaled cannabinoids have reported bioavailabilities
ranging from 2-56%, with an average of about 30% (Huestis (2007) Chem.
Biodivers. 4:1770 1804; McGilveray (2005) Pain Res. Manag. 10 Suppl.
A:15A 22A). This variability is mainly due to differences in smoking dynamics.
Cannabinoids that are absorbed through the mucous membranes in the mouth
(buccomucosal application) have bioavailabilities of around 13% (Karschner et
al. (2011) Clin. Chem. 57:66 75). By contrast, when cannabinoids are
ingested, bioavailability is typically reduced to about 6% (Karschner et al.
(2011) Clin. Chem. 57:66 75).
Lexaria s patent-pending cannabinoid lipid-infusion technology
is based in part on the goal of achieving much higher cannabinoid
bioavailability than conventional means of oral cannabinoid ingestion.
Oral bioavailability into or approaching the range typical of
smoked or inhaled cannabinoids would be potentially disruptive to the entire
medical marijuana sector because it would offer patients an efficient option to
reduce or even eliminate the need for smoking or inhalation delivery while
simultaneously improving conventional edible cannabinoid formats.
To this end, the Company will undertake certain laboratory
testing in the coming months to further characterize potentially transformative
aspects of the technology and will report the outcome upon completion.
Benefits of the patent-pending technology, include:
| 1) | A positive social health outcome through reduction of smoking of cannabinoids; |
| 2) | Improved confidence in consistent delivery of THC or CBD through oral ingestion; |
| 3) | Lower cost to consumers relative to conventional edible formats through higher rate of active ingredient delivery; |
| 4) | Easy and convenient active ingredient delivery through many readily available common everyday foods. |
| 5) | A disruptive competitive advantage for Lexaria versus any company that delivers THC or CBD through any other format, including traditional smoking. |
By their nature, new inventions are unpredictable and not
always entirely understood in advance. Many complex technologies are being
pursued by the broader food and drug industries in relation to more effective
delivery of drugs and other ingredients because their traditional oral
bioavailability may be poor. Solid lipid nanoparticles, for example, have
demonstrated improvements in bioavailability of some Class II, III, and IV drugs
as much as 2-25 fold as seen below:
The US FDA recommended high fat meals for food-effect
studies because such fatty meals (800 1000 cal, 50% 65% fat, 25% 30%
carbohydrates and 15% 20% proteins) affect GI physiology and maximize drug
transfer into the systemic circulation. (Food and Drug Administration,
Guidance for industry: food-effect bioavailability and fed bioequivalence
studies, food and drug administration. www.fda.gov)
Maximizing bioavailability is a common aim throughout the food,
pharmaceutical and drug industries since efficiencies in delivering active
ingredients also deliver many benefits.
Lexaria is a food sciences company focused on the delivery of
cannabinoid compounds procured from legal, agricultural hemp, through gourmet
foods based upon its proprietary infusion technologies. www.lexariaenergy.com
ViPovaTM uses only legal hemp oil extracts, grown
from agricultural hemp in locations where it is legal to do so, in
ViPovaTM-branded tea. ViPovaTM uses its patent-pending
process to infuse concentrated amounts of CBD within lipids in its tea,
providing more bioactivity and comfort to
the body during the absorption process. Only ViPovaTM has this ground-breaking technology for CBD/lipid infusion. www.vipova.com
FOR FURTHER INFORMATION PLEASE CONTACT:
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations,
cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if,"
"believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company's best judgment based upon
current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is
no assurance that the Company will be able to raise required working capital. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and
maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that existing capital is sufficient for
the Company's needs or that it will need to attempt to raise additional capital. There is no assurance that any planned corporate activity, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance
that any cannabinoid-based product will promote, assist, or maintain any beneficial human health conditions whatsoever. There is no assurance that the cannabinoid/lipid infusion technology will provide any increase in bioavailability to any
individual person. There is no assurance that patent-pending applications will result in granted patents, or that competing companies, in their normal course of business, might not introduce other unrelated inventions superior to the Company's
own. No statement herein has been evaluated by the Food and Drug Administration (FDA). ViPovaTM products are not intended to diagnose, treat, cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.